Published on 24/12/2025

Understanding the Influence of WHO PQ on African Pharmaceutical Approvals

The World Health Organization (WHO) Prequalification (PQ) program plays a crucial role in the acceptance and recognition of medical products in various African markets. For pharmaceutical companies seeking to penetrate these markets, understanding the implications of WHO PQ on regulatory approvals is essential. This article aims to provide a step-by-step tutorial on navigating the Africa regulatory landscape, focusing on WHO PQ’s influence on approvals by national regulatory authorities, including the National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria, the South African Health Products Regulatory Authority (SAHPRA), and the East African Community’s regulatory efforts.

1. Introduction to WHO PQ and its Relevance to African Approvals

The WHO PQ program was established to help ensure that medications and vaccines are safe, effective, and of high quality. The program’s influence on African regulatory approvals cannot be overstated. Several African countries, particularly those with less developed regulatory frameworks, rely on WHO PQ as a benchmark for their own evaluation processes. Understanding how WHO PQ operates and its criteria can aid pharmaceutical companies in crafting a global regulatory strategy that aligns with regional requirements.

Emerging markets are characterized by diverse regulatory landscapes that often vary significantly from those in more developed markets like the US and Europe. Therefore, engaging in Africa regulatory consulting services pharma becomes imperative for companies looking to establish a foothold in these regions. The WHO PQ program provides a framework that can facilitate entry and assure quality, fostering greater trust among healthcare providers and the public.

2. The Role of NAFDAC, SAHPRA, and EDA in Pharmaceutical Approvals

While the WHO PQ provides an international standard, each African country has its unique regulatory bodies, notably NAFDAC, SAHPRA, and the East African Community (EAC). When designing a global regulatory strategy, it is vital to consider their specific roles, guidelines, and approval processes.

2.1 National Agency for Food and Drug Administration and Control (NAFDAC)

NAFDAC, Nigeria’s regulatory authority, is responsible for ensuring the safety and efficacy of drugs, food products, and dietary supplements. The agency’s frameworks incorporate WHO PQ specifications, particularly for products intended for public use. Companies targeting Nigeria must ensure that their products meet both NAFDAC and WHO PQ requirements. The following steps will help in achieving successful NAFDAC approval:

• Step 1: Ensure your product is prequalified by WHO. NAFDAC recognizes WHO PQ products, expediting the approval process.
• Step 2: Prepare all documentation required for NAFDAC submission, including quality, safety, and efficacy data, in alignment with ICH guidelines.
• Step 3: Submit an application to NAFDAC for evaluation. The typical review processes involve thorough inspections and assessments.
• Step 4: Address any queries raised by NAFDAC during the review process promptly, ensuring transparency and compliance.
• Step 5: After receiving approval, continuously monitor regulatory updates from NAFDAC to ensure ongoing compliance.

2.2 South African Health Products Regulatory Authority (SAHPRA)

SAHPRA plays a similar role in South Africa, overseeing drug registration and ensuring public health safety. To align products for SAHPRA approval, follow this process:

• Step 1: Engage with the SAHPRA guidelines on registration, which incorporates WHO PQ as a strong recommendation for quality assessment.
• Step 2: Collect and compile the necessary data according to the SAHPRA submission format, including clinical trial data and pharmacovigilance plans.
• Step 3: Submit your application through the SAHPRA regulatory portal and pay any applicable fees.
• Step 4: Remain responsive to any regulatory requests for additional information that SAHPRA may issue during the review process.
• Step 5: Ensure to keep abreast of SAHPRA’s regulatory updates and protocols that may change over time.

2.3 East African Community (EAC) and Regulatory Harmonization

The EAC comprises six Member States – Burundi, Kenya, Rwanda, South Sudan, Tanzania, and Uganda – actively pursuing regulatory harmonization to facilitate pharmaceutical approvals across the region. Here are the steps to align with the EAC framework:

• Step 1: Familiarize yourself with the EAC’s regional guidelines, which are informed by WHO PQ standards.
• Step 2: Collaborate with other stakeholders in the region through the EAC’s regulatory working groups to stay ahead of upcoming guidelines.
• Step 3: Prepare documentation that meets EAC regulations, emphasizing the common market benefits of prequalification.
• Step 4: Facilitate inter-agency dialogues among member countries for smoother approvals and knowledge sharing.
• Step 5: Monitor the progress and impacts of reforms in EAC health policies that could affect your product registrations.

3. The Impact of WHO PQ on Regional Priority Setting

With WHO PQ establishing a global standard for pharmaceutical products, its influence extends into the regional priority settings of African regulatory authorities. This influence is pivotal for pharmaceutical companies aiming to align their products more effectively with emerging market regulatory submissions. Understanding the priorities set by WHO PQ can significantly enhance a company’s regulatory strategy.

Being cognizant of WHO PQ’s list of prequalified products allows companies to prioritize their submissions based on market needs and regulatory acceptance. For example:

• Disease Burden: Products aimed at prevalent diseases (such as malaria, tuberculosis, and HIV) are prioritized under WHO PQ. Aligning product development accordingly increases chances of acceptance.
• Public Health Emergencies: In cases of public health crises, WHO PQ can expedite approvals of vaccines and treatments that fulfill immediate needs.
• Quality Assurance: Products previously assessed and listed by WHO PQ inspire confidence among national regulatory authorities, facilitating quicker approvals and enhancing brand credibility.

4. Aligning Global Strategies with Local Realities

Engaging in global regulatory strategy requires an acute understanding of local realities, balancing international best practices with specific regional requirements. Failure to bridge this gap can result in costly delays and potential product rejections. Here are strategic steps for aligning global strategies with local regulations:

• Step 1: Conduct a thorough analysis of the regulatory environments in the targeted African countries to appreciate their specific demands and workflows.
• Step 2: Appoint local experts or consultants with expertise in Africa regulatory consulting services pharma to offer insights into market dynamics and regulatory expectations.
• Step 3: Adapt your product development and submission plans based on feedback from these local experts to better meet the requirements of NAFDAC, SAHPRA, and EAC.
• Step 4: Collaborate with local partners who have established connections and experience in navigating the local regulatory landscapes.
• Step 5: Evaluate and refine your approach continuously based on the evolving regulatory framework in each jurisdiction.

5. Best Practices for Successful Regulatory Submissions in Africa

Successful regulatory submissions in African countries require adherence to stringent guidelines alongside an appreciation of local contexts. The following best practices can enhance submission success:

• Step 1: Develop comprehensive validation data—ensuring adherence to ICH-GCP guidelines—which can withstand scrutiny during regulatory reviews.
• Step 2: Create thorough documentation tailored to the expectations of local entities, incorporating WHO PQ standards as necessary.
• Step 3: Ensure transparency throughout the submission process to build trust and facilitate smoother interactions with regulatory authorities.
• Step 4: Utilize technology to track submission progress, deadlines, and responses from regulatory bodies to maintain a responsive approach.
• Step 5: Foster relationships with key opinion leaders and stakeholders to enhance credibility and support for product placements.

6. Conclusion: Strategic Considerations for Pharma Firms in Africa

Navigating regulatory landscapes in Africa presents unique challenges and opportunities for pharmaceutical companies. Understanding the significance of WHO PQ in streamlining approvals through NAFDAC, SAHPRA, and the EAC is crucial for developing an effective market entry strategy. Aligning global regulatory strategies to local realities, while focusing on best practices for regulatory submissions, can greatly enhance a company’s chances of success.

By acknowledging these steps and implementing them in your practice, companies can ensure compliance with FDA EMA MHRA alignment and leverage the growing markets in Africa while improving their global reach.

To remain competitive, businesses must stay aware of ongoing changes in regulations and WHO PQ standards, thus ensuring that they are well-positioned to respond to the evolving landscape of pharmaceutical regulations in Africa.